Hepatology International

, Volume 4, Issue 3, pp 621–627

Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients

  • Chung-Feng Huang
  • Ming-Yen Hsieh
  • Jeng-Fu Yang
  • Wu-Cheng Chen
  • Ming-Lun Yeh
  • Ching-I Huang
  • Chia-Yen Dai
  • Ming-Lung Yu
  • Zu-Yau Lin
  • Shinn-Chern Chen
  • Wan-Long Chuang
  • Jee-Fu Huang
Original Article

DOI: 10.1007/s12072-010-9200-8

Cite this article as:
Huang, CF., Hsieh, MY., Yang, JF. et al. Hepatol Int (2010) 4: 621. doi:10.1007/s12072-010-9200-8
  • 61 Downloads

Abstract

Background/aims

Serum high sensitivity C-reactive protein (hs-CRP) is a surrogate marker for cardiovascular disease risks and related mortality. However, the features of hs-CRP in chronic HCV infection (CHC) patients have not been fully addressed. This study aimed to elucidate the characteristics of hs-CRP and its correlation with clinical profiles in CHC patients.

Methods

Ninety-five CHC patients and 95 age- and sex-matched healthy controls were enrolled for serum hs-CRP level, biochemical, and metabolic profiles examinations. Sequential changes of hs-CRP levels in CHC patients receiving peginterferon/ribavirin combination therapy were also evaluated.

Results

The mean hs-CRP level of CHC patients was significantly higher than that of healthy controls (0.97 ± 0.11 vs. 0.24 ± 0.07 mg/L, P < 0.001). There was no significant correlation between hs-CRP and both virological and histological factors. CHC patients with a high LDL-C level had significantly higher mean hs-CRP (1.38 ± 0.20 mg/L) than that of patients without (0.59 ± 0.06 mg/L) (P < 0.001). Hs-CRP level was significantly decreased in 83 patients after peginterferon/ribavirin combination therapy (0.24 vs. 0.62 mg/L, P < 0.001), particularly in 68 patients achieving a sustained virological response (0.25 vs. 0.64 mg/L, P < 0.001).

Conclusion

CHC patients had a higher hs-CRP level than healthy controls which could be ameliorated after peginterferon/ribavirin combination therapy.

Keywords

High sensitivity C-reactive protein Hepatitis C virus Antiviral therapy 

Copyright information

© Asian Pacific Association for the Study of the Liver 2010

Authors and Affiliations

  • Chung-Feng Huang
    • 1
    • 2
    • 3
  • Ming-Yen Hsieh
    • 1
    • 4
  • Jeng-Fu Yang
    • 1
    • 5
  • Wu-Cheng Chen
    • 2
  • Ming-Lun Yeh
    • 1
    • 6
  • Ching-I Huang
    • 1
    • 6
  • Chia-Yen Dai
    • 1
    • 5
    • 7
    • 8
  • Ming-Lung Yu
    • 1
    • 4
    • 8
  • Zu-Yau Lin
    • 1
    • 8
  • Shinn-Chern Chen
    • 1
    • 8
  • Wan-Long Chuang
    • 1
    • 8
  • Jee-Fu Huang
    • 1
    • 6
    • 9
  1. 1.Hepatobiliary Division, Department of Internal MedicineKaohsiung Medical University HospitalKaohsiungTaiwan
  2. 2.Department of Preventive Medicine, Kaohsiung Municipal Ta-Tong HospitalKaohsiung Medical University HospitalKaohsiungTaiwan
  3. 3.Department of Occupational Medicine, Kaohsiung Municipal Ta-Tong HospitalKaohsiung Medical University HospitalKaohsiungTaiwan
  4. 4.Department of Internal Medicine, Kaohsiung Municipal Ta-Tong HospitalKaohsiung Medical University HospitalKaohsiungTaiwan
  5. 5.Department of Preventive MedicineKaohsiung Medical University HospitalKaohsiungTaiwan
  6. 6.Graduate Institute of Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  7. 7.Department of Occupational MedicineKaohsiung Medical University HospitalKaohsiungTaiwan
  8. 8.Faculty of Internal Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  9. 9.Department of Internal Medicine, Kaohsiung Municipal Hsiao-Kang HospitalKaohsiung Medical University HospitalKaohsiungTaiwan

Personalised recommendations